Actively Recruiting
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
Led by Zibo Municipal Hospital · Updated on 2025-07-25
20
Participants Needed
1
Research Sites
256 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of Tislelizumab combined with platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB/C-IV non-squamous non-small cell lung cancer. This study aims to provide more treatment options for patients with locally advanced non-small cell lung cancer.
CONDITIONS
Official Title
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-75 years old, any gender
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Confirmed stage IIIB/C-IV non-squamous non-small cell lung cancer by cytology or histology
- No prior systemic therapy for lung cancer
You will not qualify if you...
- Uncontrolled autoimmune diseases
- Autoimmune reactions in past 6 months that are unresolved or unstable despite treatment
- Known driver gene mutations such as EGFR, ALK, BRAF, ROS1, RET, MET
- Prior systemic therapy or adjuvant/neoadjuvant therapy with recurrence less than 3 months from last treatment
- Known allergies or contraindications to study drug or its excipients
- Pregnant or lactating females, or positive pregnancy test at baseline
- Childbearing potential patients unwilling to use effective contraception during and 6 months after trial
- Comorbidities or conditions affecting protocol compliance or deemed unsuitable by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zibo Municipal Hospital
Zibo, Shandong, China, 250000
Actively Recruiting
Research Team
Q
Qiang Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here